Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hoff

Showing results (301-310 of 318) with videos related to

Pageof 32
Sort By:
Nature Medicine|June 15, 2007
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorPatricia A Darrah, Dipti T Patel, Paula M De Luca, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2018
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection TrialSara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 19, 2025
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers' and Healthcare Providers' PerspectivesCaroline M A Mussert, Nadia C W Kamminga, Evelien S van Hoorn, et al.
Vaccine|June 7, 2015
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trialHennie Geldenhuys, Helen Mearns, David J C Miles, et al.
Vaccine|December 3, 2014
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in humanJaap T van Dissel, Simone A Joosten, Søren T Hoff, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
Scientific Reports|April 8, 2017
Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6Morten Ruhwald, Lena de Thurah, Davis Kuchaka, et al.
Plos One|December 10, 2014
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trialKlaus Reither, Lynn Katsoulis, Trevor Beattie, et al.
Research and Practice in Thrombosis and Haemostasis|September 27, 2023
Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banksLorynn Teela, Michiel A J Luijten, Isolde A R Kuijlaars, et al.
Pageof 32

Showing results (301-310 of 318) with videos related to

Sort By:
Pageof 32
Nature Medicine|June 15, 2007
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorPatricia A Darrah, Dipti T Patel, Paula M De Luca, et al.
Vaccine|January 25, 2011
Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infectionJaap T van Dissel, Darius Soonawala, Simone A Joosten, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2018
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection TrialSara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 19, 2025
Experiences and Needs Regarding Information Provision in Children With Haemophilia: A Qualitative Study on Caregivers' and Healthcare Providers' PerspectivesCaroline M A Mussert, Nadia C W Kamminga, Evelien S van Hoorn, et al.
Vaccine|June 7, 2015
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trialHennie Geldenhuys, Helen Mearns, David J C Miles, et al.
Vaccine|December 3, 2014
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in humanJaap T van Dissel, Simone A Joosten, Søren T Hoff, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
Scientific Reports|April 8, 2017
Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6Morten Ruhwald, Lena de Thurah, Davis Kuchaka, et al.
Plos One|December 10, 2014
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trialKlaus Reither, Lynn Katsoulis, Trevor Beattie, et al.
Research and Practice in Thrombosis and Haemostasis|September 27, 2023
Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banksLorynn Teela, Michiel A J Luijten, Isolde A R Kuijlaars, et al.
Pageof 32